SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aventis exits JV with Novartis

14 Dec 2010 Evaluate

Aventis Pharma, the Indian arm of French multinational drug maker Sanofi-Aventis, will sell its 49 per cent stake in vaccine manufacturing unit, Chiron Behring Vaccines, to its joint venture partner Novartis Vaccines and Diagnostics for $ 22.4 million (Rs 101 crore).

The deal between the multinational drug firms would draw curtains to a two-year-old battle in India over rights to India's largest selling anti-rabies vaccine, Rabipur. It had sales of close to Rs 118 crore two years ago with a market share of about 70 per cent. The brand belongs to Chiron Behring Vaccines. Novartis had objected to the renewal of a 10-year marketing licence to Aventis Pharma last February.Until February 2009, Aventis manufactured Rabipur at its plant in Ankleshwar in Gujarat, while Novartis Healthcare was the distributor of the vaccines in the country.

After losing the rights of Rabipur, Aventis Pharma's arm, Shanta Biotech, launched group company Sanofi Pasteur's brand Verorab in the Indian market. This was challenged by Novartis in the Bombay High Court, citing conflict of interest. The court allowed the petition and Aventis is appealing the decision. India’s anti-rabies market is estimated to have an annual size of Rs 250 crore.crackcrack

Sanofi India Share Price

3578.55 18.75 (0.53%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×